Anesthesia · Injectable
The FDA's approval of Anthea Pharma's generic Propofol represents a significant shift in the anesthesia market, introducing increased competition that could impact pricing strategies. Pharma strategy teams should closely monitor market dynamics and competitor responses to assess potential impacts on revenue and market share.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/18/2026, 6:31:28 AM
Assessment confidence: 86% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Anthea Pharma's generic Propofol represents a significant shift in the anesthesia market, introducing increased competition that could impact pricing strategies. Pharma strategy teams should closely monitor market dynamics and competitor responses to assess potential impacts on revenue and market share. Regulatory context from FDA (FDA AP — PROPOFOL (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (14 high-relevance).
Anthea Pharma's entry into the Propofol market may pressure pricing and market share for current competitors. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Anesthesia · Injectable, 4 regulatory and 1 competitive items passed relevance filtering for Anthea Pharma.
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). This approval allows Anthea Pharma to enter the market with a generic version of Propofol, potentially increasing competition against existing brands.
Regulatory risk is concentrated around FDA AP — PROPOFOL (ORIG) (FDA). Entity match (anthea pharma); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, PMDA. The approval of ANDA220857 indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.
FDA AP — PROPOFOL (ORIG)
FDAhigh relevance
Entity match (anthea pharma); Regulatory pathway relevance (nda)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted
PMDAhigh relevance
Moderate corpus alignment
FDA document
View sourceStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceEvaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourcePartial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceInsect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceLavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceThe role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Anthea Pharma's generic Propofol represents a significant shift in the anesthesia market, introducing increased competition that could impact pricing strategies. Pharma strategy teams should closely monitor market dynamics and competitor responses to assess potential impacts on revenue and market share.
The entry of a generic version of Propofol may lead to price reductions and increased competition, affecting the revenue of existing brands in the market.
The approval of ANDA220857 indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.
Monitor market uptake of Anthea Pharma's Propofol and any responses from existing manufacturers.
Track for follow-up milestones; no immediate action required.